![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
DELAWARE | 0-28298 | 94-3154463 | ||
(State of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
ITEM 5.02 | DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. |
| the aggregate number of authorized shares of common stock available for issuance under the Incentive Plan was increased by 3,000,000 shares; | ||
| the size of the annual restricted stock award to continuing non-employee directors was increased such that, beginning in 2011, on the last business day of March each year, continuing non-employee directors will receive a combination of an option to purchase 5,000 shares of common stock and a restricted stock bonus award covering 3,000 shares of common stock, with such numbers of shares reduced pro rata if any non-employee director has served on the Board of Directors for less than one year; and | ||
| on the date of the 2010 annual meeting of stockholders of Onyx, each continuing non-employee director received a transitional restricted stock bonus award covering 1,000 shares of common stock with such numbers of shares reduced pro rata if any non-employee director had served on the Board of Directors for less than one year as of March 31, 2010. |
ITEM 5.07 | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
(a) | All of the nominees of the Board of Directors were elected to serve until Onyxs annual meeting of stockholders in 2013. The nominees were: Corinne H. Nevinny; 45,420,879 shares of common stock voted for, none against, 645,770 withheld, and 9,354,045 broker non-votes; and Thomas G. Wiggans; 41,482,387 shares of common stock voted for, none against, 4,584,262 withheld, and 9,354,045 broker non-votes. The term of office of directors Magnus Lundberg and N. Anthony Coles, M.D. continues until Onyxs annual meeting of stockholders in 2011. The term of office of directors Paul Goddard, Ph.D., Antonio J. Grillo-López, M.D., and Wendell Wierenga, Ph.D. continues until Onyxs annual meeting of stockholders in 2012. | ||
(b) | The stockholders approved the Incentive Plan Amendments: 33,650,708 shares of common stock voted for, 12,394,916 against, 21,025 abstaining, and 9,354,045 broker non-votes. | ||
(c) | The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst &Young LLP as Onyxs independent registered public accounting firm for the fiscal year ending December 31, 2010: 48,976,511 shares of common stock voted for, 6,413,078 against, 31,105 abstaining and zero broker non-votes. |
ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
Exhibit Number | Description | |
10.13(i)
|
2005 Equity Incentive Plan, as amended |
Date: May 28, 2010 |
ONYX PHARMACEUTICALS, INC.
|
|||
By: | /s/ Matthew K. Fust | |||
Matthew K. Fust | ||||
Executive Vice President and Chief Financial Officer | ||||
Exhibit Number | Description | |
10.13(i)
|
2005 Equity Incentive Plan, as amended |
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions